# China NMPA Drug Inspection - Hengtuo Group Guangxi Shengkang Pharmaceutical Co., Ltd. - Elderly Cough and Asthma Capsules

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hengtuo-group-guangxi-shengkang-pharmaceutical-co-ltd/74c6a274-6264-4802-8122-29607f7bbade/
Source feed: China

> China NMPA drug inspection for Hengtuo Group Guangxi Shengkang Pharmaceutical Co., Ltd. published November 19, 2019. Drug: Elderly Cough and Asthma Capsules. On November 19, 2019, the Chongqing Municipal Drug Administration announced that four batches of drugs from four distinc

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Chongqing Municipal Drug Administration Regarding 4 Batches of Drugs That Failed to Meet Regulations
- Company Name: Hengtuo Group Guangxi Shengkang Pharmaceutical Co., Ltd.
- Publication Date: 2019-11-19
- Drug Name: Elderly Cough and Asthma Capsules
- Inspection Finding: The non-compliant item is the inspection item.
- Action Taken: The relevant directly affiliated inspection bureaus and district/county market supervision bureaus were instructed to take necessary control measures such as sealing, seizing, suspending sales, and recalling products, and to investigate and deal with the matter in accordance with relevant laws and regulations.
- Summary: On November 19, 2019, the Chongqing Municipal Drug Administration announced that four batches of drugs from four distinct manufacturers failed to meet established quality standards following testing by local drug inspection institutes. Shenyang Shenlong Pharmaceutical Co., Ltd.'s Qianlielongbitong Tablets (batch 20180602) were found non-compliant in both appearance and general inspection parameters. Harbin Sanmu Pharmaceutical Factory's Qiangli Zhike Ning Capsules (batch JN190201) and Hengtuo Group Guangxi Shengkang Pharmaceutical Co., Ltd.'s Laoren Kechuan Capsules (batch 180304) both failed general inspection requirements. Similarly, Shaanxi Ziguang Chenji Pharmaceutical Co., Ltd.'s Huanglian Shangqing Pills (batch 817035) also failed general inspection. These violations indicate potential issues with the drugs' quality characteristics, safety, efficacy, or manufacturing uniformity, as evaluated against national drug standards including the Chinese Pharmacopoeia. In response, the Chongqing Municipal Drug Administration mandated immediate control measures. These required actions included sealing, seizing, suspending sales, and recalling the affected drug batches, with further processing to be conducted in accordance with relevant laws and regulations to safeguard public health.

Company: https://www.globalkeysolutions.net/companies/hengtuo-group-guangxi-shengkang-pharmaceutical-co-ltd/1a91fa3c-3b01-458f-8ff6-7e717cd401a0/